Arkendu Chatterjee

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 259 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer

Robin M.J.M. van Geel, Josep Tabernero, Elena Élez et al. · Cancer Discovery · 2017 · 230 citations · Full text

Medicine, Oncology, Pharmacology +17

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Manal F. Abdelmalek, Arun J. Sanyal, Atsushi Nakajima et al. · Clinical Gastroenterology and Hepatology · 2023 · 99 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Rohit Loomba, Arun J. Sanyal, Atsushi Nakajima et al. · Clinical Gastroenterology and Hepatology · 2023 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Timothy A. Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto et al. · The Lancet Respiratory Medicine · 2021 · 78 citations

Medicine, Oncology, Pharmacology +10